Compare Dell Technologies Inc (DELL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs GeneDx Holdings Corp — how do they compare? Dell Technologies Inc trades at $587.41 (market cap $365.31B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Dell Technologies Inc is far larger — about 180.8× GeneDx Holdings Corp's market cap, and Dell Technologies Inc pays a 0.44% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and GeneDx Holdings Corp for 19 Days on average.
| DELL | WGS | |
|---|---|---|
Market Cap | $365.31B | $2.02B |
Volume | 5,121,365 | 734,640 |
Sector | Technology | Health |
52-Week High | $588.67 | $167.51 |
52-Week Low | $111.10 | $34.51 |
Typical Hold Time | 57 Days | 19 Days |
Enterprise Value | $388.20B | $2.05B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $575.33, down 0.63% on the day, but maintains a bullish technical trend with strong support near $566. The stock is buoyed by robust AI server demand, with Q2 2026 EPS beating estimates by 43% and fiscal 2027 revenue guidance raised to approximately $192 billion. Recent news highlights a 20% dividend increase and a $74 billion AI server backlog, fueling investor optimism.
Outlook remains positive given explosive AI-driven growth, but risks include execution on massive orders and competitive pressures. Analysts are largely bullish with a $566.35 consensus target, though the current price slightly exceeds it. Shareholders should monitor margin sustainability and debt levels amid rapid expansion.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
